- Home
- ATCH vs ALZN Comparison
ATCH vs ALZN Comparison
Compare ATCH & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- ALZN
- Stock Information
- Founded
- ATCH 2022
- ALZN 2016
- Country
- ATCH United States
- ALZN United States
- Employees
- ATCH N/A
- ALZN N/A
- Industry
- ATCH
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- ATCH
- ALZN Health Care
- Exchange
- ATCH Nasdaq
- ALZN Nasdaq
- Market Cap
- ATCH 2.5M
- ALZN 2.3M
- IPO Year
- ATCH N/A
- ALZN 2021
- Fundamental
- Price
- ATCH $0.18
- ALZN $2.35
- Analyst Decision
- ATCH
- ALZN Strong Buy
- Analyst Count
- ATCH 0
- ALZN 1
- Target Price
- ATCH N/A
- ALZN $180.00
- AVG Volume (30 Days)
- ATCH 30.3M
- ALZN 217.3K
- Earning Date
- ATCH 08-27-2025
- ALZN 09-10-2025
- Dividend Yield
- ATCH N/A
- ALZN N/A
- EPS Growth
- ATCH N/A
- ALZN N/A
- EPS
- ATCH N/A
- ALZN N/A
- Revenue
- ATCH $14,825,966.00
- ALZN N/A
- Revenue This Year
- ATCH N/A
- ALZN N/A
- Revenue Next Year
- ATCH N/A
- ALZN N/A
- P/E Ratio
- ATCH N/A
- ALZN N/A
- Revenue Growth
- ATCH 1066.77
- ALZN N/A
- 52 Week Low
- ATCH $0.14
- ALZN $2.06
- 52 Week High
- ATCH $26.94
- ALZN $135.54
- Technical
- Relative Strength Index (RSI)
- ATCH 46.62
- ALZN 35.09
- Support Level
- ATCH $0.17
- ALZN $2.14
- Resistance Level
- ATCH $0.22
- ALZN $2.44
- Average True Range (ATR)
- ATCH 0.03
- ALZN 0.17
- MACD
- ATCH 0.00
- ALZN -0.03
- Stochastic Oscillator
- ATCH 22.77
- ALZN 23.97
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.